This trial entitled biomarker-integrated approaches of targeted therapy for lung cancer elimination (BATTLE) enrolled 255 patients with pre-treated non-small cell lung cancer who were randomized into one of four arms based on biomarker analysis: erlotinib, vandetanib, erlotinib plus bexarotene, or sorafenib.
In our randomized cross-over designs, subjects were randomized into one of the two following sequences: paper then touch-screen or touch-screen then paper.
Parturients were randomized into one of two groups using computer generated random allocation (block randomization, block size 4).
The left two panels show results for individuals who were employed prior to the experiment, who provided survey information on earnings, and who were randomized into one of the treatment groups (N=760).
After recording a proteinuria level ≥300 mg/dL on one occasion, mice were randomized into one of two dosing groups and dosed subcutaneously (s.c).
Female adults (n = 150) with three established PONV risk factors based on Apfel's score were randomized into one of three study groups.
Subsequently, participants gave their informed consent by clicking on the appropriate button and were randomized into one of two groups.
Animals were randomized into one of the three groups and ventilated according to randomization for the following 24 hours.
Twenty-one patients (15.4%) of 149 refused to participate in the trial and 7 patients were excluded from the study based on the elimination criteria; the remaining 121 women were randomized into one of the two groups (58 for UAE and 63 for myomectomy) and they underwent appropriate therapy (Table 1).
Individual patients were randomized into one of two conditions: the HERA or assessment only.
The defects of the single-defect knees were randomized into one of seven groups presented in Table 1.
